Eli Lilly and Company vs Shell plc: Strategic Comparison

This in-depth comparison examines Eli Lilly and Company and Shell plc across revenue, market value, business model, competitive positioning, and long-term growth strategy. Whether you are researching Eli Lilly and Company on its own, evaluating Shell plc, or weighing the two companies side by side, the breakdown below highlights where each company leads and where the gap between Eli Lilly and Company and Shell plc is widest.

On the headline numbers, Eli Lilly and Company reports annual revenue of $65.2B against $316.0B for Shell plc, while their respective market capitalizations stand at $700.0B and $210.0B. Eli Lilly and Company is headquartered in United States and Shell plc operates from United Kingdom, and those different home markets shape how each company competes.

Eli Lilly and Company: Revenue at Eli Lilly went from $28.5 billion in 2022 to $45 billion in 2024. That $16.5 billion increase in two years is not a corporate turnaround story — it's the commercial harvest of a single molecule: tirzepatide, sold as Mounjaro for diabetes and Zepbound for obesity. The drug became the fastest pharmaceutical product ever to reach $5 billion in annual sales, transforming a 148-year-old Midwestern company into one of America's most valuable corporations at a $700 billion market capitalization. The scientific lineage matters. Lilly produced the world's first commercially available insulin in 1923, giving type 1 diabetic patients who had previously faced certain death a reason to survive. That 1923 achievement planted the company in incretin biology — the study of gut hormones that regulate insulin secretion and appetite — where it would spend decades building intellectual and clinical depth. Tirzepatide is not a lucky discovery. It is the commercial output of that sustained investment. The SURMOUNT-5 trial made a specific claim that reshaped the competitive landscape: tirzepatide produced approximately 47% greater relative weight loss than semaglutide (Wegovy) in a direct head-to-head comparison. That's not a nuanced statistical edge — it's a clinically meaningful difference that gives physicians a reason to prescribe Zepbound over Novo Nordisk's product. The supply shortage that followed was the kind of problem that only hits companies whose demand has genuinely exceeded expectations. Retatrutide, Lilly's triple receptor agonist in Phase 3 development, showed average body weight reduction of approximately 24.2% over 48 weeks in a Phase 2 trial. If that number holds in Phase 3, it would represent the most effective pharmacological weight loss data ever published.

Shell plc: Shell controls approximately 14 percent of global LNG supply — more than any other single company — and uses that position to buy LNG where prices are low and sell it where prices are high. The arbitrage capability comes not from owning the most gas wells but from owning the most LNG infrastructure: liquefaction plants, shipping vessels, regasification terminals, and the trading desk with the market intelligence to exploit price differentials across 70 countries simultaneously. The SS Murex, which Marcus Samuel sent through the Suez Canal in 1892 as the world's first purpose-built bulk oil tanker, was Shell's first logistics arbitrage play. The LNG trading operation is the 2024 version of the same idea. The company generated $316 billion in revenue in 2023 — down from $381 billion in 2022 and up from $261 billion in 2021 — from 103,000 employees operating across exploration, production, refining, chemicals, and low-carbon energy in more than 70 countries. Net income of $19.4 billion on $316 billion in revenue is a 6.1 percent margin, which understates the profitability of the upstream business because refining and chemicals margins run much thinner. The $210 billion market capitalization prices Shell as an energy company in transition rather than a pure oil and gas company, reflecting both the genuine low-carbon investments and the strategic ambiguity about how fast that transition needs to proceed. The 2021 Dutch court ruling ordering Shell to cut absolute carbon emissions 45 percent by 2030 — the first time a corporation was legally compelled to align with the Paris Agreement — set a precedent that Shell has contested on appeal while simultaneously making voluntary emissions commitments. CEO Wael Sawan, who took over from Ben van Beurden in 2023, has recalibrated the clean energy ambition toward profitability, pulling back from some renewable investments that were consuming capital without generating adequate returns. Shell lost its entire Russian oil portfolio to Soviet nationalization in 1917 without compensation. Mexican operations were nationalized in 1938. The company's history of operating in politically complex jurisdictions and absorbing nationalization losses without permanent destruction is part of what makes its current 70-country footprint comprehensible — it has been rebuilt multiple times from different geographic foundations.

Eli Lilly and Company and Shell plc pursue distinct approaches to generating revenue, and understanding how each company operates is the foundation of any fair comparison between Eli Lilly and Company and Shell plc.

Eli Lilly and Company business model: Lilly endured a lost decade marked by clinical failures in Alzheimer's disease research, insulin pricing controversies that drew congressional scrutiny, and generic competition that eroded blockbuster revenues. At its most fundamental level, Lilly's revenue model is straightforward: the company invests heavily in discovering and developing novel drugs, secures patent protection and regulatory approval for those drugs, manufactures them at scale, and sells them at premium prices to patients, healthcare systems, and payers. Insulin pricing has been a politically sensitive issue for Lilly, and in 2023 the company proactively announced it would cap monthly out-of-pocket costs for all insulin products at $35, a decision that absorbed short-term revenue impact but significantly reduced reputational and legislative risk. From a revenue geography perspective, the United States consistently represents the largest single market, accounting for approximately 65 percent of total revenues in 2024, reflecting both the premium pricing environment in American healthcare and the company's deep commercial infrastructure across hospitals, specialty pharmacies, and managed care organizations. The company's pricing and reimbursement strategy reflects the complex political economy of American pharmaceutical markets. Lilly's gross-to-net discount structure — the gap between list prices and the actual net prices after rebates, chargebacks, and discounts to payers and pharmacy benefit managers — has grown substantially as managed care organizations have exerted pricing pressure. Pricing and access policy represents a politically charged challenge with direct financial consequences. The Inflation Reduction Act of 2022 enable the Centers for Medicare and Medicaid Services to negotiate prices directly for high-expenditure drugs, and multiple Lilly products may become subject to negotiated pricing as the program expands in scope. The broader debate over pharmaceutical pricing, including congressional investigations and state-level legislative efforts, creates an ongoing environment of policy uncertainty that affects revenue planning and investor sentiment. Additionally, dozens of biotechnology companies and larger pharmaceutical corporations are developing oral GLP-1 agonists, next-generation dual and triple agonist molecules, and combination weight loss therapies that could fragment the market and compress Lilly's pricing power over the medium term.

Shell plc business model: Samuel commissioned one, negotiated Rothschild oil supply from Baku, and in 1892 sent the SS Murex — the world's first purpose-built bulk oil tanker — through the canal with 4,000 tons of Russian kerosene bound for Japan. The more strategically interesting part is convenience retail: the coffee, food, packaged goods, and services sold inside forecourt shops, where margins are significantly higher than fuel. The premium performance claims that justify higher retail pricing for V-Power fuel and Helix motor oil rest on demonstrable F1-derived technology rather than marketing assertion. This gives Shell's lubricants business a pricing architecture that commodity lubricant producers cannot match. **Chemicals and Products** manufactures petrochemicals (ethylene, propylene, benzene, and other plastics and chemical feedstocks) and refined petroleum products (jet fuel, diesel, marine fuel, bitumen) at integrated refinery-chemical complexes. Shell has been rationalizing this portfolio for a decade, converting underperforming refineries to 'energy and chemicals parks' — integrated facilities that crack a wider variety of feedstocks into higher-value chemical products rather than commodity transportation fuels — and closing or divesting assets where the competitive position is structurally weak. American LNG is sold at prices linked to Henry Hub (the US benchmark natural gas price) plus a liquefaction fee, rather than at prices indexed to crude oil as traditional long-term LNG contracts specify. Shell has adapted by increasing its US LNG offtake agreements to include Henry Hub-linked supply alongside its traditional oil-indexed portfolio, giving its trading book the flexibility to offer buyers different price structures and hedge its own exposure to any single pricing regime. In retail fuel, where the product being sold is physically identical across brands, brand recognition supports a modest but real pricing premium — research consistently shows that consumers pay marginally more per liter at Shell stations than at unbranded stations, and that Shell motorists perceive the V-Power premium fuel formulation as meaningfully different from standard fuel, justifying an additional price premium. Marcus Samuel commissioned the Glasgow naval architect William Gray to design one to the Canal Company's exact specifications, negotiated a contract with a Whitby shipbuilder for its construction, secured a long-term oil supply agreement with the Rothschilds' Baku operation, and simultaneously set up a distribution network of oil storage depots in Singapore, Penang, Bangkok, and Hong Kong — all before the tanker was even built. Within three years, Marcus had commissioned eight more tankers — the Conch, the Clam, the Cowrie, the Elax, the Murex, the Neritina, the Patella, the Pecten, the Volute (each named after a seashell species) — and established a distribution network that was taking measurable market share from Standard Oil's Far East business.

The durability of a company's moat often decides long-term winners. Here is how the competitive advantages of Eli Lilly and Company stack up against those of Shell plc.

Eli Lilly and Company competitive advantage: What makes Lilly's story particularly compelling is not just the scale of its recent success but the specific American geography it inhabits. The competitive landscape in which Eli Lilly operates has been radically reshaped over the past decade, both by the emergence of the GLP-1 drug class as a genuine blockbuster category and by the parallel evolution of oncology and immunology into scientifically sophisticated, targeted medicine domains where first-mover advantages and data depth matter enormously. Verzenio's revenue trajectory suggests it may eventually become the category leader despite entering the market after Ibrance, reflecting the value of superior clinical data over first-mover advantage in targeted oncology. The injectable nature of current tirzepatide formulations represents a patient acceptance barrier that, if removed through an effective oral alternative, would dramatically expand the addressable market. Eli Lilly's competitive advantages are rooted in four interconnected sources that, in combination, create a defensible position in the global pharmaceutical industry that goes beyond any single product success. This domain expertise is not merely historical; it manifests today in Lilly's pipeline of next-generation cardiometabolic molecules including orforglipron (an oral GLP-1 receptor agonist that could eliminate the injection barrier for millions of patients), retatrutide (a triple receptor agonist showing extraordinary weight loss results in Phase 2 trials — an average of 24.2 percent body weight reduction over 48 weeks), and other compounds targeting the intersection of metabolic disease, cardiovascular risk, and kidney function. Trust built through reliable insulin supply over a century translates into prescriber confidence in Lilly's newer products, creating a commercial starting advantage that newer entrants cannot replicate quickly. Fourth, Lilly's manufacturing infrastructure, while currently capacity-constrained, represents a long-term competitive moat. The technical complexity of sterile injectable biologics manufacturing creates meaningful barriers to generic and biosimilar entry, and the company's investments in dedicated tirzepatide manufacturing capacity will eventually provide scale advantages over potential competitors who face the same steep learning curves and capital requirements. By October 1923, Lilly was producing insulin on a commercial scale sufficient to supply diabetic patients across North America, and the company had developed an extract with substantially higher potency and reliability than earlier preparations.

Shell plc competitive advantage: The North Sea in the 1970s, deepwater Gulf of Mexico in the 1980s and 1990s, ultradeep offshore Brazil in the 2000s — each frontier was harder than the last, and each drove the engineering innovation that eventually became Shell's most durable competitive moat. Beginning with investments in Qatar, Australia, and Nigeria in the 1970s and 1980s — before LNG had proven commercially viable at scale — Shell built long-term supply contracts and trading infrastructure that eventually became the world's largest LNG portfolio. Shell has steadily high-graded this portfolio since 2015, selling mature, high-cost, or politically complex assets — including its oil sands operations in Canada, some North Sea assets, and various onshore operations in developed markets — to concentrate production in deepwater and LNG, where Shell has genuine technical competitive advantage and where cost curves are typically lower than onshore alternatives. Deepwater operations require specialized drilling technology, subsea engineering expertise, and project management capability that creates real barriers to entry. CEO Sawan has explicitly signaled that Shell will not compete in utility-scale solar and wind generation where it lacks structural competitive advantages over pure-play renewable energy developers. What makes Shell's story distinctive among oil majors is the specific character of its competitive advantages. Shell is making selective bets in EV charging, hydrogen, and CCS where it believes its existing assets and expertise create structural advantages. It is deliberately not competing in areas — utility-scale wind, solar — where it sees no edge over dedicated renewable developers. Shell's most durable competitive advantages are its LNG trading capability and its deepwater engineering expertise. The competitive moat is a function of time: twenty to forty years of patient investment that cannot be compressed regardless of how much capital a new entrant brings. Brand equity provides a third advantage that is harder to quantify but commercially meaningful. Finally, Shell's scale in lubricants — the world's largest lubricants marketer by volume through Shell Helix, Rimula, and Tellus product lines — creates cost advantages in base oil procurement and manufacturing that smaller competitors cannot match, enabling either lower prices or higher margins depending on competitive conditions in specific markets. Third, selectively building low-carbon positions where Shell has genuine competitive advantage and can generate competitive returns. The strategy explicitly de-emphasizes offshore wind and utility-scale solar, where Shell concluded it does not have structural advantages over pure-play renewable energy developers who can build at lower cost with simpler operating models. The focus is on EV charging (using the existing forecourt real estate and customer relationships), hydrogen for industrial use where Shell's chemical park infrastructure creates co-location advantages, carbon capture and storage where Shell's geological expertise translates, and the transition fuels business (LNG for marine and road transport, biofuels). Each of these areas either leverages Shell's existing assets and competencies or requires scale advantages that Shell's size provides. The logistics problem, Marcus Samuel understood, was that nobody had found a way to ship that cheap Russian kerosene to the enormous and rapidly growing kerosene market of Asia — for lighting in an era before electrification was widespread — without the cost advantages evaporating on a months-long voyage around the Cape of Good Hope.

Future prospects matter as much as current results. The growth strategies below explain how Eli Lilly and Company and Shell plc each plan to expand from here.

Eli Lilly and Company growth strategy: That insulin partnership with the University of Toronto did not merely save lives; it established Lilly's identity as a science-first organization willing to pursue difficult biological problems across decades rather than quarters. Yet the company continued investing heavily in its research and development infrastructure, spending consistently between 20 and 25 percent of revenues on R&D even in lean years. Retevmo (selpercatinib), a RET kinase inhibitor for RET-altered cancers including certain lung and thyroid malignancies, and Jaypirca (pirtobrutinib), a BTK inhibitor for mantle cell lymphoma and chronic lymphocytic leukemia, represent Lilly's next-generation oncology assets with significant growth trajectories. Europe and Japan represent the next largest markets, with significant growth in emerging markets including China, where Lilly has maintained commercial operations for decades. This investment includes new sterile injectable fill-finish capacity and active pharmaceutical ingredient manufacturing to eliminate supply constraints that limited Zepbound and Mounjaro availability through much of 2023 and into 2024. The Indianapolis-based pharmaceutical company, which has survived Prohibition, the Great Depression, two World Wars, the AIDS crisis, multiple patent cliffs, and a decade of Alzheimer's drug failures, has in the early 2020s assembled what many analysts characterize as the most compelling pharmaceutical growth story of the current era. Ricks prioritized pipeline discipline over diversification, investing deeply in a small number of therapeutic areas where Lilly had genuine scientific depth rather than spreading resources thinly across many programs with mediocre differentiation. The company now invests more in R&D in absolute dollar terms than it generated in total revenues just fifteen years ago, illustrating both how dramatically the company has grown and how aggressively it is reinvesting to sustain that growth trajectory. For investors, healthcare professionals, policymakers, and patients, Lilly's evolution represents a case study in what pharmaceutical companies can achieve when long-term scientific commitment meets the right commercial moment. Lilly's competitive positioning in immunology is solid but not dominant, and the company's strategic priority is increasingly to defend existing Taltz revenues while investing in next-generation immunology candidates that could create new market leadership positions. This rate of growth is nearly unprecedented for a company of Lilly's scale in any industry, and it reflects almost entirely the commercial launch of tirzepatide across its Mounjaro and Zepbound indications. While Lilly's multi-billion-dollar manufacturing investment program is expected to alleviate these constraints by 2026 and 2027, the ramp-up period presents real financial and competitive risk, particularly as rival GLP-1 products from Novo Nordisk and potential new entrants compete for the same prescriber base and pharmacy shelf space. The irony is, Second, Lilly's brand equity among endocrinologists, cardiologists, and primary care physicians reflects decades of relationship-building through clinical education, medical affairs programs, and drug performance in real-world settings. Eli Lilly's growth strategy, as articulated through company investor presentations, earnings calls, and strategic communications under CEO David Ricks, rests on three interconnected pillars: maximizing the commercial potential of approved assets through indication expansion and market access improvement; sustaining pipeline productivity through disciplined internal R&D and targeted external business development; and building the manufacturing infrastructure necessary to support global demand at scale. The indication expansion strategy for tirzepatide is already well advanced. External business development has accelerated meaningfully under Ricks, reflecting a strategic recognition that internal R&D, while productive, cannot alone sustain the pipeline density required to replace revenue from products facing eventual patent expiry. Manufacturing investment represents the operational backbone of the growth strategy, with over $23 billion committed through 2027 to building capacity that will eliminate the supply constraints that have limited tirzepatide access and revenue since commercial launch. The trajectory of Eli Lilly over the next five to ten years is unusually legible by pharmaceutical industry standards, in large part because the company's near-term growth drivers are already approved and scaling and its longer-term pipeline candidates include multiple assets with multi-billion-dollar peak sales potential that have progressed to late-stage clinical development. Among the estimated 100 million Americans with obesity, fewer than 5 percent were receiving any pharmacological treatment as of 2024, suggesting an addressable population that could sustain revenue growth for many years even without new indications. New tirzepatide label expansions under investigation include heart failure with preserved ejection fraction (a trial already demonstrating positive results), sleep apnea, fatty liver disease (NASH/MASH), chronic kidney disease, and potentially cancer risk reduction. In Alzheimer's disease, donanemab (Kisunla) faces the challenge of building commercial infrastructure around a complex treatment model — patients require amyloid confirmation testing, infusion center visits, and MRI monitoring — but the underlying unmet medical need remains enormous, and Lilly is investing in diagnostic partnerships and infusion center networks to remove access barriers. The city was growing rapidly, positioned at the intersection of multiple rail lines that would increasingly define American commerce in the post-war era, and Lilly recognized both a business opportunity and a professional calling. He invested in analytical equipment to test raw materials before they entered production, a practice so unusual in the trade that it became a marketing point — Lilly medicines carried certificates of analysis years before regulatory bodies existed to require such documentation. This commitment to scientific integrity was not merely altruistic; it was a business strategy rooted in the belief that healthcare professionals, if given a choice, would prefer reliably effective medicines over cheaper alternatives that varied wildly in potency and purity. The company grew steadily through the late nineteenth century, expanding its product line from elixirs and tonics to a broader range of pharmaceuticals, moving into gelatin-coated capsules (a technology that significantly improved patient acceptance of medications) in the 1890s, and building a growing export business in Central and South America. The lesson of insulin — that patient, rigorous scientific investment in understanding complex biological mechanisms could produce far-reaching therapeutic outcomes — informed Lilly's research philosophy throughout the twentieth century and provides direct intellectual lineage to the GLP-1 and incretin research that would eventually produce tirzepatide seven decades later.

Shell plc growth strategy: It was Deterding who understood that the only way to resist Standard Oil's predatory pricing strategy was to match its scale — and that merger was faster than organic growth. The defining tension of Shell's current moment is the gap between the infrastructure it spent 130 years building and the future it must navigate. Whether Shell can simultaneously maximize returns from aging hydrocarbon assets and invest enough in low-carbon energy to emerge viable in a decarbonized world is the central question of its next chapter — and one the company's own management does not yet have a complete answer to. Operating through five segments — Integrated Gas and LNG Trading (largest profit contributor), Upstream oil and gas, Marketing and retail, Chemicals and Products, and Renewables and Energy Solutions — Shell is navigating the most consequential strategic inflection in its history: how to simultaneously maximize cash from the hydrocarbon assets it built over 130 years while investing in the low-carbon alternatives that the world's climate commitments require. CEO Wael Sawan, appointed January 2023, has prioritized near-term cash returns and capital discipline while maintaining the 2050 net-zero commitment but scaling back specific renewable energy investment targets set by his predecessor. Shell's business model is an integrated energy value chain — from finding hydrocarbons in the ground to delivering energy products to end consumers — augmented by a growing portfolio of low-carbon businesses. The integration creates value by capturing margin at multiple points across the chain rather than specializing in one activity, and it provides resilience: when oil prices collapse, trading and marketing margins sometimes expand; when gas prices surge, the LNG business generates windfall profits that offset upstream weakness. This arbitrage capability is the most financially valuable part of Shell's business and the hardest for competitors to replicate without decades of contract-building and infrastructure investment. Upstream now generates approximately 25 – 30% of adjusted earnings and is managed with explicit capital discipline: Shell aims to hold production roughly flat rather than growing it, using upstream cash flows to fund shareholder returns and Integrated Gas growth rather than chasing volume. Shell has invested systematically in convenience formats including Shell Select convenience stores, Deli2Go fresh food concepts, and branded café partnerships, aiming to shift the economic center of gravity of a Shell visit from fuel dispensing to in-store purchase. The segment generates approximately 8% of earnings in a typical year, though with high volatility: chemical margins expand during periods of tight supply and compress sharply during downturns when global chemical capacity exceeds demand. The Rhineland facility in Germany and the Deer Park refinery (jointly owned with Pemex until Shell acquired full control) in Texas represent the energy-and-chemicals-park model Shell is evolving toward. It includes Shell's investments in offshore wind (through joint ventures including the Hollandse Kust Noord project in the Netherlands), the Shell Recharge EV charging network targeting 500,000 charge points by 2025, the Holland Hydrogen I green hydrogen plant in Rotterdam (upon completion, Europe's largest), carbon capture and storage investments (Quest CCS in Canada, Sleipner in Norway), and carbon credits trading. Instead, Shell's renewables strategy focuses on sectors where its existing infrastructure creates genuine edges: EV charging networks that use the existing forecourt real estate and customer relationships, hydrogen for industrial users that can be co-located with existing chemical parks, and CCS as a service to industrial emitters where Shell's geology and reservoir engineering expertise translates. The segment currently generates approximately 2% of earnings — a figure Shell management expects to grow, though the timeline is contested by analysts who note the current investment pace is insufficient to grow the segment materially within a decade. The company that helped build the petroleum infrastructure of the modern world now faces the reckoning that the world built on oil is generating: a climate crisis that requires the industry Shell pioneered to fundamentally transform itself within a generation. TotalEnergies has been the most aggressive in renewables investment among the supermajors, building a significant utility-scale renewable electricity portfolio and positioning itself as a multi-energy company with credible claims in solar, wind, and batteries alongside gas and oil. ExxonMobil and Chevron have been the most explicit in prioritizing near-term hydrocarbon returns, arguing that global energy demand requires continued oil and gas investment and that the energy transition will proceed at the pace of real-world deployment rather than policy aspiration. Shell under Wael Sawan has moved toward the ExxonMobil/Chevron end of the spectrum since 2023, scaling back the specific low-carbon investment commitments made by predecessor Ben van Beurden while maintaining the 2050 net-zero headline commitment. This financial outperformance has given Shell management more credibility in arguing that its energy transition strategy — slower investment in renewables, higher near-term cash returns — is the right approach. The company's most useful financial lens is adjusted earnings — a measure that strips out identified items including asset impairments, divestment gains, fair value movements on derivatives, and tax effects — which management and investors use as the primary profitability indicator. The dividend was rebuilt after the 2020 cut to approximately $1.00 per share annually (on the ADS basis), with targeted 4% annual growth. Shell faces a dual challenge almost unique in corporate history: it must simultaneously extract maximum value from assets that will eventually be stranded by the energy transition while investing at scale in the technologies and infrastructure of the new energy system. The risk of expanding climate litigation adds both direct legal costs and strategic uncertainty to Shell's capital planning. The Russian exit demonstrated both the political risk inherent in energy assets in authoritarian states and the speed with which geopolitical events can strand investments that had previously appeared commercially secure. European gasoline demand has been declining at approximately 2 – 3% annually as EV adoption accelerates, with the rate of decline expected to steepen through the 2030s as new EV model prices reach parity with internal combustion vehicles. Shell Recharge offers EV charging at a growing number of stations, but the economics of EV charging are structurally different from liquid fuel retail: EV sessions take longer (reducing throughput per bay), require higher capital investment per charging point, and currently earn lower margins per session than fuel dispensing. Building a comparable LNG trading position today would require signing multi-decade supply contracts with major LNG producers — most of which are already fully contracted with Shell and other majors — building or securing access to shipping and terminal capacity, and developing the trading desk expertise and relationships that allow realization of the theoretical arbitrage in practice. Shell's growth strategy under Wael Sawan is built around three explicit priorities. First, growing and high-grading the LNG business — signing new long-term supply contracts, expanding the trading book, and capturing the LNG demand growth in Asia without requiring proportional capital increases given the existing infrastructure base. New projects already in development (LNG Canada, Qatar North Field expansion) will expand volume; the priority is capturing that volume at high margins through trading optimization rather than chasing volume for its own sake. Second, generating maximum cash from the upstream oil portfolio through capital discipline and operational efficiency rather than production growth. The strategy involves continuously high-grading the portfolio: selling mature, high-cost, or politically complex assets and concentrating production in the most profitable deepwater and unconventional basins. LNG demand growth in Asia represents the most durable structural tailwind. India is building significant LNG import infrastructure — new regasification terminals, gas distribution pipelines, and industrial gas connections — at a pace that could make it the world's third-largest LNG importer within a decade, behind Japan and China. Shell's existing supply relationships and trading infrastructure in the region are well positioned to capture this growth. China's LNG demand, which grew explosively through 2021 before moderating, is expected to resume growth as industrial activity expands and coal-to-gas switching continues in coastal cities. European LNG demand, elevated since the 2022 Russian gas cutoff, is expected to remain structurally higher than pre-2022 levels for at least a decade as Europe builds long-term LNG supply security rather than returning to Russian pipeline dependence. New LNG supply projects Shell has equity in or offtake from — including LNG Canada (a greenfield LNG export terminal in British Columbia partly owned by Shell, with first LNG exports expected in 2025), Qatar's North Field expansion (the world's largest LNG expansion program, adding approximately 64 million tonnes per annum of new supply capacity by 2030), and additional US Gulf Coast export capacity — will increase Shell's contracted supply portfolio through the late 2020s, supporting volume growth in the Integrated Gas segment. Zijlker died before the company became profitable, leaving it in the hands of managers who struggled with both geology (the field was more technically difficult than early surveys suggested) and capital (Dutch investors remained wary of a speculative colonial enterprise). He cut costs at every operation, improved logistics, and then expanded geographically with methodical aggression: into fields in Romania, Russia, Venezuela, and Trinidad, building a diversified production base that Standard Oil could not threaten in all geographies simultaneously. Standard Oil's strategy of temporary price cuts in specific markets — designed to bankrupt or acquire competitors — was sustainable only by a company large enough to absorb losses in one market while profiting in dozens of others.

A closer look at the financial trajectory of Eli Lilly and Company and Shell plc rounds out the comparison.

Eli Lilly and Company: $9.3 billion spent on research and development in fiscal year 2024 — a number that exceeds Lilly's entire revenue base in 2009. That reinvestment rate, sustained over years, is the financial explanation for tirzepatide's commercial performance. Drugs of this clinical quality don't emerge from modest R&D budgets. Net income reached $10.59 billion in FY2025 on $65.2B in revenue, a 23.5% net margin that reflects the pricing power of a drug that genuinely outperforms its competition. The revenue trajectory has been steep: $28.3 billion in 2021, $28.5 billion in 2022, $34.1 billion in 2023, $65.2B in FY2025. Each year's jump is larger than the last, driven by tirzepatide's expansion across indications and geographies. The supply shortage controversy in 2023 had a real financial component. Manufacturing capacity for GLP-1 drugs requires specialized equipment and long lead times. Lilly has committed billions in capital expenditure to expand manufacturing — but the gap between demand and supply means some prescription revenue is being left on the table during a period when competitive dynamics are most favorable. The Loxo Oncology acquisition in 2019 cost approximately $8 billion. The oncology pipeline it delivered — including selpercatinib and other targeted therapies — now contributes revenue that diversifies Lilly's earnings away from the GLP-1 concentration risk. Market capitalization of $700 billion prices in continued GLP-1 dominance and successful Phase 3 outcomes for retatrutide. Either of those assumptions failing would reprice the stock significantly.

Shell plc: Revenue of $316 billion in 2023 — the most recent full-year figure — fell from the $381 billion peak in 2022 as oil and gas prices normalized from post-Ukraine invasion levels. The 2022 peak was not a sustainable baseline; it reflected a commodity price spike driven by geopolitical disruption rather than structural demand growth. Revenue of $183 billion in 2020 was the pandemic trough. The volatility across four years — $183 billion, $261 billion, $381 billion, $316 billion — illustrates why energy company financial analysis requires cycle-adjusted metrics rather than year-over-year comparisons. Net income of $19.4 billion on $316 billion in revenue (6.1 percent margin) reflects the blended economics of upstream production, LNG trading, refining, chemicals, and retail. The upstream business produces at much higher margins; the downstream segments, particularly chemicals and retail fuel, operate on thin margins that reduce the overall blended rate. LNG trading, where Shell's 14 percent global market share provides arbitrage opportunities across price differentials, is the segment with the most distinctive economics. The $210 billion market capitalization implies the market values Shell at roughly $2 billion per percentage point of global LNG market share — a rough but useful heuristic for understanding what investors are pricing as the company's most durable competitive advantage. The BG Group LNG assets, acquired in 2016, are central to that position. The Dutch court ruling's requirement for a 45 percent absolute emissions reduction by 2030 — contested on appeal — creates a potential capital allocation conflict between maintaining upstream production levels (which generate the cash flows funding clean energy investment) and reducing the absolute emissions that come primarily from upstream operations. Wael Sawan's repositioning prioritizes returns over pace of energy transition, which resolves the conflict in favor of shareholders in the near term while leaving the regulatory trajectory uncertain.